cancer immunotherapy

March 17, 2017March 17, 2017

Kite’s CAR T-cell Therapy Helps Aggressive Lymphoma Patients, Clinical Trial Shows

News

Eighty-two percent of patients with refractory aggressive lymphoma have responded to Kite Pharma‘s KTE-C19 chimeric antigen receptor (CAR) T-cell therapy, and 36 percent have achieved complete remission, according to preliminary results of a clinical ... Read more

May 24, 2016May 24, 2016

Anti-Tumor Activity of Natural Killer T-cells Boosted by Molecules in Lymphoma Study in Mice

News

Natural killer T-cells (NKT) are important in immunotherapy due to their ability to effectively localize to tumor sites and attack cancer cells. Their clinical application, however, has been hampered by a lack of ... Read more

February 25, 2016February 25, 2016

Lymphoma and Leukemia Clinical Trials of Immunotherapy Drug to Treat Resistant Cancers Now Recruiting Patients

News

Three new clinical trials aim to assess the safety and efficacy of a new cancer immunotherapy treatment, KTE-C19, in patients with three types of treatment-resistant blood cancers — refractory aggressive ... Read more

January 26, 2016January 26, 2016

New Hodgkin Lymphoma Combo Therapy of Keytruda and AFM13 to Move into Clinical Trial

News

Affimed Therapeutics N.V. , a German clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reports that it has entered into an immuno-oncology clinical research collaboration with ... Read more